
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7904972/publications.pdf Version: 2024-02-01



MALINONG

#	Article	IF	CITATIONS
1	The gut microbiome and mental health: advances in research and emerging priorities. Molecular Psychiatry, 2022, 27, 1908-1919.	7.9	39
2	ADORA1-driven brain-sympathetic neuro-adipose connections control body weight and adipose lipid metabolism. Molecular Psychiatry, 2021, 26, 2805-2819.	7.9	8
3	Transcription factor POU3F2 regulates TRIM8 expression contributing to cellular functions implicated in schizophrenia. Molecular Psychiatry, 2021, 26, 3444-3460.	7.9	16
4	The gut microbiome modulates gut–brain axis glycerophospholipid metabolism in a region-specific manner in a nonhuman primate model of depression. Molecular Psychiatry, 2021, 26, 2380-2392.	7.9	102
5	Rare Functional Variants Associated with Antidepressant Remission in Mexican-Americans. Journal of Affective Disorders, 2021, 279, 491-500.	4.1	3
6	Reduced motor cortex GABABR function following chronic alcohol exposure. Molecular Psychiatry, 2021, 26, 383-395.	7.9	8
7	Advances in autism research, 2021: continuing to decipher the secrets of autism. Molecular Psychiatry, 2021, 26, 1426-1428.	7.9	0
8	Re-assessing the catecholamine hypothesis of depression: the case of melancholic depression. Molecular Psychiatry, 2021, 26, 6121-6124.	7.9	6
9	Activation of septal OXTr neurons induces anxiety- but not depressive-like behaviors. Molecular Psychiatry, 2021, 26, 7270-7279.	7.9	12
10	Climate change and mental health: a commentary. Discover Mental Health, 2021, 1, 1.	2.0	0
11	Circulating leptin levels in patients with myalgic encephalomyelitis, chronic fatigue syndrome or fibromyalgia: a systematic review protocol. JBI Evidence Synthesis, 2021, 19, 695-701.	1.3	4
12	Personalized Pharmacotherapy: A Historical Perspective on the Pharmacogenomics of Depression. , 2021, , .		0
13	Molecular Psychiatry special issue: advances in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 5467-5470.	7.9	2
14	Extracorporeal apheresis therapy for Alzheimer disease—targeting lipids, stress, and inflammation. Molecular Psychiatry, 2020, 25, 275-282.	7.9	16
15	Using behaviour change theory to inform an innovative digital recruitment strategy in a mental health research setting. Journal of Psychiatric Research, 2020, 120, 1-13.	3.1	4
16	Landscapes of bacterial and metabolic signatures and their interaction in major depressive disorders. Science Advances, 2020, 6, .	10.3	178
17	Advances in schizophrenia research: glycobiology, white matter abnormalities, and their interactions. Molecular Psychiatry, 2020, 25, 3116-3118.	7.9	2
18	Molecular Psychiatry, August 2020: new impact factor, and highlights of recent advances in psychiatry, including an overview of the brain's response to stress during infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Molecular Psychiatry, 2020, 25, 1606-1610.	7.9	0

#	Article	IF	CITATIONS
19	The COVID-19 pandemic and epidemiologic insights from recession-related suicide mortality. Molecular Psychiatry, 2020, 25, 3445-3447.	7.9	20
20	Offensive Behavior, Striatal Glutamate Metabolites, and Limbic–Hypothalamic–Pituitary–Adrenal Responses to Stress in Chronic Anxiety. International Journal of Molecular Sciences, 2020, 21, 7440.	4.1	10
21	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis. Molecular Psychiatry, 2020, 25, 1611-1617.	7.9	70
22	Advances in depression research: second special issue, 2020, with highlights on biological mechanisms, clinical features, co-morbidity, genetics, imaging, and treatment. Molecular Psychiatry, 2020, 25, 1356-1360.	7.9	10
23	Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression. Advanced Science, 2020, 7, 1902862.	11.2	99
24	Pilot trial of a group cognitive behavioural therapy program for comorbid depression and obesity. BMC Psychology, 2020, 8, 34.	2.1	5
25	Advances in depression research: special issue, 2020, with three research articles by Paul Greengard. Molecular Psychiatry, 2020, 25, 1156-1158.	7.9	2
26	Psychiatric Disorders and Bone Emphasizing Mechanistic Trends. , 2020, , 33-42.		0
27	Perturbed Microbial Ecology in Myasthenia Gravis: Evidence from the Gut Microbiome and Fecal Metabolome. Advanced Science, 2019, 6, 1901441.	11.2	55
28	Chronic stress induces hypersensitivity of murine gastric vagal afferents. Neurogastroenterology and Motility, 2019, 31, e13669.	3.0	14
29	Post-Traumatic Stress Disorder Chronification via Monoaminooxidase and Cortisol Metabolism. Hormone and Metabolic Research, 2019, 51, 618-622.	1.5	11
30	Short-term antidepressant treatment has long-lasting effects, and reverses stress-induced decreases in bone features in rats. Translational Psychiatry, 2019, 9, 10.	4.8	9
31	Mice lacking Casp1, Ifngr and Nos2 genes exhibit altered depressive- and anxiety-like behaviour, and gut microbiome composition. Scientific Reports, 2019, 9, 6456.	3.3	15
32	From Allostatic Load to Allostatic State—An Endogenous Sympathetic Strategy to Deal With Chronic Anxiety and Stress?. Frontiers in Behavioral Neuroscience, 2019, 13, 47.	2.0	25
33	AGRP neurons modulate fasting-induced anxiolytic effects. Translational Psychiatry, 2019, 9, 111.	4.8	35
34	Has the UK Improving Access to Psychological Therapies programme and rising antidepressant use had a public health impact?. Lancet Psychiatry,the, 2019, 6, e8-e9.	7.4	14
35	The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Science Advances, 2019, 5, eaau8317.	10.3	446
36	Effect of medical student debt on mental health, academic performance and specialty choice: a systematic review. BMJ Open, 2019, 9, e029980.	1.9	111

#	Article	IF	CITATIONS
37	Neuroimmunomodulation in Major Depressive Disorder: Focus on Caspase 1, Inducible Nitric Oxide Synthase, and Interferon-Gamma. Molecular Neurobiology, 2019, 56, 4288-4305.	4.0	62
38	Stress-inducible-stem cells: a new view on endocrine, metabolic and mental disease?. Molecular Psychiatry, 2019, 24, 2-9.	7.9	21
39	The depressed heart. Heart and Mind (Mumbai, India), 2019, 3, 35.	0.6	7
40	Investigation of short tandem repeats in major depression using whole-genome sequencing data. Journal of Affective Disorders, 2018, 232, 305-309.	4.1	10
41	Current status of <i>Plasmodium knowlesi</i> vectors: a public health concern?. Parasitology, 2018, 145, 32-40.	1.5	38
42	Genetic clustering of depressed patients and normal controls based on single-nucleotide variant proportion. Journal of Affective Disorders, 2018, 227, 450-454.	4.1	7
43	The Microbiotaâ€Inflammasome Hypothesis of Major Depression. BioEssays, 2018, 40, e1800027.	2.5	91
44	Low-frequency and rare variants may contribute to elucidate the genetics of major depressive disorder. Translational Psychiatry, 2018, 8, 70.	4.8	25
45	Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement. Molecular Neurobiology, 2017, 54, 4486-4495.	4.0	38
46	Single-nucleotide variant proportion in genes: a new concept to explore major depression based on DNA sequencing data. Journal of Human Genetics, 2017, 62, 577-580.	2.3	11
47	Whole-genome single nucleotide variant distribution on genomic regions and its relationship to major depression. Psychiatry Research, 2017, 252, 75-79.	3.3	12
48	Biological and behavioural antidepressant treatment responses with the selective serotonin reuptake inhibitor fluoxetine can be determined by the environment. Molecular Psychiatry, 2017, 22, 484-484.	7.9	4
49	A novel strategy for clustering major depression individuals using whole-genome sequencing variant data. Scientific Reports, 2017, 7, 44389.	3.3	14
50	SSRI antidepressant use potentiates weight gain in the context of unhealthy lifestyles: results from a 4-year Australian follow-up study. BMJ Open, 2017, 7, e016224.	1.9	17
51	Investigation of copy number variation in subjects with major depression based on whole-genome sequencing data. Journal of Affective Disorders, 2017, 220, 38-42.	4.1	9
52	Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer. PLoS ONE, 2017, 12, e0178454.	2.5	46
53	APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer's disease. Molecular Psychiatry, 2016, 21, 916-924.	7.9	89
54	2.2 Translational Research in Endocrinology and Neuroimmunology Applied to Depression. , 2015, , 119-131.		1

#	Article	IF	CITATIONS
55	Valproic acid enhances neuronal differentiation of sympathoadrenal progenitor cells. Molecular Psychiatry, 2015, 20, 941-950.	7.9	26
56	Temporal Gene Expression in the Hippocampus and Peripheral Organs to Endotoxin-Induced Systemic Inflammatory Response in Caspase-1-Deficient Mice. NeuroImmunoModulation, 2015, 22, 263-273.	1.8	4
57	Response to Uher et al American Journal of Psychiatry, 2015, 172, 396-398.	7.2	1
58	Whole Exome Sequencing of Extreme Morbid Obesity Patients: Translational Implications for Obesity and Related Disorders. Genes, 2014, 5, 709-725.	2.4	19
59	Clinical Outcomes and Genome-Wide Association for a Brain Methylation Site in an Antidepressant Pharmacogenetics Study in Mexican Americans. American Journal of Psychiatry, 2014, 171, 1297-1309.	7.2	33
60	Leptin Signaling and Hyperparathyroidism: Clinical and Genetic Associations. Journal of the American College of Surgeons, 2014, 218, 1239-1250e4.	0.5	8
61	Effects of Leptin Deficiency and Replacement on Cerebellar Response to Food-Related Cues. Cerebellum, 2013, 12, 59-67.	2.5	29
62	Chromaffin cells: the peripheral brain. Molecular Psychiatry, 2012, 17, 354-358.	7.9	33
63	Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arquivos Brasileiros De Endocrinologia E Metabologia, 2012, 56, 597-607.	1.3	152
64	Dopamine D2/D3 receptor availability in genetically leptin-deficient patients after long-term leptin replacement. Molecular Psychiatry, 2012, 17, 352-353.	7.9	10
65	Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian Journal of Endocrinology and Metabolism, 2012, 16, 549.	0.4	99
66	Elevated plasma prolactin in abstinent methamphetamine-dependent subjects. American Journal of Drug and Alcohol Abuse, 2011, 37, 62-67.	2.1	9
67	CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics Journal, 2011, 11, 108-112.	2.0	46
68	Associations between adipokines and obesity-related cancer. Frontiers in Bioscience - Landmark, 2011, 16, 1634.	3.0	138
69	Sequence polymorphisms of MC1R gene and their association with depression and antidepressant response. Psychiatric Genetics, 2011, 21, 14-18.	1.1	22
70	Ten years of leptin replacement therapy. Obesity Reviews, 2011, 12, e315-23.	6.5	108
71	Long-term body weight outcomes of antidepressant–environment interactions. Molecular Psychiatry, 2011, 16, 265-272.	7.9	30
72	Short-Term Plasticity of Gray Matter Associated with Leptin Deficiency and Replacement. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1212-E1220.	3.6	39

#	Article	IF	CITATIONS
73	cGMP Signaling, Phosphodiesterases and Major Depressive Disorder. Current Neuropharmacology, 2011, 9, 715-727.	2.9	59
74	Dynamics of plasma proteome during leptin-replacement therapy in genetically based leptin deficiency. Pharmacogenomics Journal, 2011, 11, 174-190.	2.0	7
75	Advances in depression research: 2011. Molecular Psychiatry, 2011, 16, 686-687.	7.9	14
76	Pharmacogenomics of antidepressant treatment effects. Dialogues in Clinical Neuroscience, 2011, 13, 63-71.	3.7	36
77	The procognitive effects of leptin in the brain and their clinical implications. International Journal of Clinical Practice, 2010, 64, 1808-1812.	1.7	93
78	Brain-derived neurotrophic factor in depression: a male problem?. Molecular Psychiatry, 2010, 15, 227-227.	7.9	6
79	Pharmacogenomics of antidepressants: what is next?. Molecular Psychiatry, 2010, 15, 445-445.	7.9	6
80	Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy. Arquivos Brasileiros De Endocrinologia E Metabologia, 2010, 54, 690-697.	1.3	77
81	Pathophysiological basis of cardiovascular disease and depression: a chicken-and-egg dilemma. Revista Brasileira De Psiquiatria, 2010, 32, 181-191.	1.7	22
82	Leptin Replacement Prevents Weight Loss-Induced Metabolic Adaptation in Congenital Leptin-Deficient Patients. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 851-855.	3.6	53
83	Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. Journal of Psychopharmacology, 2010, 24, 1755-1763.	4.0	45
84	Candidate Biomarkers for Systemic Inflammatory Response Syndrome and Inflammation: A Pathway for Novel Translational Therapeutics. NeuroImmunoModulation, 2010, 17, 359-368.	1.8	5
85	Leptin Levels and Alzheimer Disease. JAMA - Journal of the American Medical Association, 2010, 303, 1478.	7.4	18
86	Association of PDE11A global haplotype with major depression and antidepressant drug response. Neuropsychiatric Disease and Treatment, 2009, 5, 163.	2.2	24
87	Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent. Clinical Pharmacology: Advances and Applications, 2009, 1, 1.	1.2	2
88	Cellular Immunity Before and After Leptin Replacement Therapy. Journal of Pediatric Endocrinology and Metabolism, 2009, 22, 1069-74.	0.9	16
89	Novel Sequence Variations in the Brain-Derived Neurotrophic Factor Gene and Association With Major Depression and Antidepressant Treatment Response. Archives of General Psychiatry, 2009, 66, 488.	12.3	151
90	Deconvolution of Insulin Secretion, Insulin Hepatic Extraction Post-hepatic Delivery Rates and Sensitivity during 24-hour Standardized Meals: Time Course of Glucose Homeostasis in Leptin Replacement Treatment. Hormone and Metabolic Research, 2009, 41, 142-151.	1.5	27

#	Article	IF	CITATIONS
91	Effects of Leptin Replacement on Risk Factors for Cardiovascular Disease in Genetically Leptin-deficient Subjects. Hormone and Metabolic Research, 2009, 41, 164-167.	1.5	12
92	Leptin and insulin sensitivity: reply to Oral and Burant. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E396-E396.	3.5	0
93	Global meta-analysis of the C-11377G alteration in the ADIPOQ gene indicates the presence of population-specific effects: challenge for global health initiatives. Pharmacogenomics Journal, 2009, 9, 42-48.	2.0	14
94	Congenital leptin deficiency and thyroid function. Thyroid Research, 2009, 2, 11.	1.5	27
95	Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Molecular Psychiatry, 2009, 14, 1105-1118.	7.9	150
96	Repeated antidepressant therapy increases cyclic GMP signaling in rat hippocampus. Neuroscience Letters, 2009, 466, 149-153.	2.1	12
97	Phosphodiesterase genes and antidepressant treatment response: A review. Annals of Medicine, 2009, 41, 177-185.	3.8	29
98	Chronic imipramine downregulates cyclic AMP signaling in rat hippocampus. NeuroReport, 2009, 20, 307-311.	1.2	9
99	Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Molecular Psychiatry, 2008, 13, 800-812.	7.9	270
100	Is the Worldwide Epidemic of Obesity a Communicable Feature of Globalization?. Experimental and Clinical Endocrinology and Diabetes, 2008, 116, S30-S32.	1.2	22
101	Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E1401-E1408.	3.5	46
102	Effects of Leptin on Lipid Metabolism. Hormone and Metabolic Research, 2008, 40, 572-574.	1.5	16
103	Elevated Stress-Hemoconcentration in Major Depression Is Normalized by Antidepressant Treatment: Secondary Analysis from a Randomized, Double-Blind Clinical Trial and Relevance to Cardiovascular Disease Risk. PLoS ONE, 2008, 3, e2350.	2.5	27
104	Leptin Replacement Improves Cognitive Development. PLoS ONE, 2008, 3, e3098.	2.5	120
105	The Metabolic Syndrome - A Global Challenge for Prevention. Hormone and Metabolic Research, 2007, 39, 777-780.	1.5	58
106	Caspase 1 deficiency reduces inflammation-induced brain transcription. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7205-7210.	7.1	36
107	Leptin replacement alters brain response to food cues in genetically leptin-deficient adults. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18276-18279.	7.1	193
108	Suicidality Scores During Double-Blind Fluoxetine and Desipramine Treatment in Mexican Americans. Journal of Clinical Psychopharmacology, 2007, 27, 99-102.	1.4	4

#	Article	IF	CITATIONS
109	The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans. NeuroReport, 2007, 18, 1291-1293.	1.2	83
110	Effects of leptin on intake of specific micro- and macronutrients in a woman with leptin gene deficiency studied off and on leptin at stable body weight. Appetite, 2007, 49, 594-599.	3.7	24
111	Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1317-1321.	4.8	46
112	Pharmacogenomics of neuroimmune interactions in human psychiatric disorders. Experimental Physiology, 2007, 92, 807-811.	2.0	21
113	Effects of leptin replacement on macro- and micronutrient preferences. International Journal of Obesity, 2007, 31, 1859-1863.	3.4	17
114	Hypothalamic–pituitary-end organ function in women with bipolar depression. Psychoneuroendocrinology, 2007, 32, 279-286.	2.7	11
115	Modeling of the Temporal Patterns of Fluoxetine Prescriptions and Suicide Rates in the United States. PLoS Medicine, 2006, 3, e190.	8.4	41
116	Approaching the shared biology of obesity and depression: the stress axis as the locus of gene–environment interactions. Molecular Psychiatry, 2006, 11, 892-902.	7.9	228
117	150 years of Sigmund Freud: what would Freud have said about the obesity epidemic?. Molecular Psychiatry, 2006, 11, 1070-1072.	7.9	23
118	Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15124-15129.	7.1	147
119	CYP2C9 and clinical response to antidepressant drugs in Mexican-Americans. Clinical Pharmacology and Therapeutics, 2005, 77, P24-P24.	4.7	1
120	Depression, antidepressants and suicidality: a critical appraisal. Nature Reviews Drug Discovery, 2005, 4, 165-171.	46.4	89
121	The evolution of signaling complexity suggests a mechanism for reducing the genomic search space in human association studies. Molecular Psychiatry, 2005, 10, 14-26.	7.9	13
122	Peripheral is Central to the question. Molecular Psychiatry, 2005, 10, 421-422.	7.9	13
123	Pharmacogenomics in psychiatry: clinical issues to be considered. Molecular Psychiatry, 2005, 10, 615-615.	7.9	10
124	Elevated cortisol levels and increased rates of diabetes and mood symptoms in Soviet Union-born Jewish immigrants to Germany. Molecular Psychiatry, 2005, 10, 974-975.	7.9	31
125	Pharmacogenomics in psychiatry: genomic considerations. Molecular Psychiatry, 2005, 10, 713-713.	7.9	3
126	Depression and anxiety symptoms in diabetic patients on continuous subcutaneous insulin infusion (CSII). Molecular Psychiatry, 2005, 10, 975-976.	7.9	16

#	Article	IF	CITATIONS
127	Effect of Leptin Replacement on Brain Structure in Genetically Leptin-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2851-2854.	3.6	169
128	Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8303-8308.	7.1	90
129	Microanalysis of eating behavior of three leptin deficient adults treated with leptin therapy. Appetite, 2005, 45, 75-80.	3.7	51
130	Teaching community, occupational and family medicine at the National University of Singapore: past, present and future. Annals of the Academy of Medicine, Singapore, 2005, 34, 102C-107C.	0.4	4
131	Willingness to donate blood samples for genetic research: a survey from a community in Singapore. Clinical Genetics, 2004, 65, 45-51.	2.0	63
132	Simultaneous and Continuous 24-Hour Plasma and Cerebrospinal Fluid Leptin Measurements: Dissociation of Concentrations in Central and Peripheral Compartments. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 258-265.	3.6	32
133	Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4531-4536.	7.1	445
134	Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10434-10439.	7.1	308
135	From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nature Reviews Drug Discovery, 2004, 3, 136-151.	46.4	192
136	St John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response. Molecular Psychiatry, 2004, 9, 237-251.	7.9	54
137	Translational research in psychiatry: pitfalls and opportunities for career development. Molecular Psychiatry, 2004, 9, 117-117.	7.9	7
138	Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry, 2004, 9, 442-473.	7.9	661
139	Back to where it all started: monoamines and behavior—from drug responses to genes. Molecular Psychiatry, 2004, 9, 427-427.	7.9	4
140	Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Molecular Psychiatry, 2004, 9, 1075-1082.	7.9	159
141	Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Pharmacogenomics Journal, 2004, 4, 403-406.	2.0	62
142	Clinical Implications of Genetic Polymorphism of <i>CYP2D6</i> in Mexican Americans. Annals of Internal Medicine, 2004, 140, W-48.	3.9	4
143	Sequence and function in pharmacogenomics. Pharmacogenomics Journal, 2003, 3, 123-123.	2.0	1
144	Approaches to dissecting mechanisms of adverse drug reactions in psychiatry: clozapine-binding sites in the bone marrow. Pharmacogenomics Journal, 2003, 3, 189-189.	2.0	2

#	Article	IF	CITATIONS
145	Social and behavioural factors associated with condom use among direct sex workers in Siem Reap, Cambodia. Sexually Transmitted Infections, 2003, 79, 163-165.	1.9	60
146	Identification, characterization, and gene expression profiling of endotoxin-induced myocarditis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14241-14246.	7.1	21
147	The interface of obesity and depression: risk factors for the metabolic. Revista Brasileira De Psiquiatria, 2003, 25, 196-197.	1.7	18
148	Cytokine Pathways in the Brain. Neurobiological Foundation of Aberrant Behaviors, 2003, , 39-53.	0.2	0
149	Autoimmunity in autism. Molecular Psychiatry, 2002, 7, 329-329.	7.9	21
150	Advances in the pharmacogenomics of adverse drug reactions. Pharmacogenomics Journal, 2002, 2, 273-273.	2.0	11
151	Patient-oriented investigation in pharmacogenomics. Pharmacogenomics Journal, 2002, 2, 137-137.	2.0	0
152	Complexity and Pharmacogenomics. Pharmacogenomics Journal, 2002, 2, 203-203.	2.0	1
153	Will pharmacogenomics guide clinical practice?. Pharmacogenomics Journal, 2002, 2, 71-71.	2.0	2
154	Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology, 2002, 162, 55-62.	3.1	24
155	Conceptualizing depression. Molecular Psychiatry, 2002, 7, 429-429.	7.9	1
156	Brain-derived neurotrophic factor (BDNF) in stress and affective disorders. Molecular Psychiatry, 2002, 7, 519-519.	7.9	41
157	Depression and cardiovascular disease: co-occurrence or shared genetic substrates?. Molecular Psychiatry, 2002, 7, 1031-1032.	7.9	20
158	Depression and obesity treatments are life saving. Nature Medicine, 2002, 8, 1336-1336.	30.7	3
159	Autonomic Nervous System–Leptin Interactions. , 2002, , 223-243.		0
160	Major Depression and the Autonomic Nervous System. , 2002, , 642-655.		0
161	Evidence-based health promotion: applying it in practice. Annals of the Academy of Medicine, Singapore, 2002, 31, 656-62.	0.4	0
162	Cytokines in the brain: From localization and function to clinical implications. NeuroImmune Biology, 2001, , 365-371.	0.2	2

#	Article	IF	CITATIONS
163	Expression of corticotropin releasing hormone receptors type I and type II mRNA in suicide victims and controls. Molecular Psychiatry, 2001, 6, 540-546.	7.9	118
164	Research and treatment approaches to depression. Nature Reviews Neuroscience, 2001, 2, 343-351.	10.2	546
165	IL-1 receptor type I gene expression in the amygdala of inflammatory susceptible Lewis and inflammatory resistant Fischer rats. Journal of Neuroimmunology, 2001, 121, 32-39.	2.3	13
166	Synchronicity of Frequently Sampled Thyrotropin (TSH) and Leptin Concentrations in Healthy Adults and Leptin-Deficient Subjects: Evidence for Possible Partial TSH Regulation by Leptin in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3284-3291.	3.6	199
167	The pharmacogenomics of depression. Pharmacogenomics Journal, 2001, 1, 175-177.	2.0	13
168	Synchronicity of Frequently Sampled Thyrotropin (TSH) and Leptin Concentrations in Healthy Adults and Leptin-Deficient Subjects: Evidence for Possible Partial TSH Regulation by Leptin in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3284-3291.	3.6	47
169	Immunological Assays for Understanding Neuroimmune Interactions. Archives of Neurology, 2000, 57, 948.	4.5	11
170	Factors Associated With Condom Use for Oral Sex Among Female Brothel-Based Sex Workers in Singapore. Sexually Transmitted Diseases, 2000, 27, 39-45.	1.7	10
171	Acute systemic inflammation up-regulates secretory sphingomyelinase <i>in vivo</i> : A possible link between inflammatory cytokines and atherogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8681-8686.	7.1	156
172	Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: Relation to hypercortisolism and corticotropin-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 325-330.	7.1	518
173	Sexually Transmitted Diseases and Condom Use Among Female Freelance and Brothel-Based Sex Workers in Singapore. Sexually Transmitted Diseases, 1999, 26, 593-600.	1.7	23
174	A prospective study of pharyngeal gonorrhoea and inconsistent condom use for oral sex among female brothel-based sex workers in Singapore. International Journal of STD and AIDS, 1999, 10, 595-599.	1.1	23
175	Sociodemographic and Lifestyle Factors Associated With Constipation in An Elderly Asian Community. American Journal of Gastroenterology, 1999, 94, 1283-1291.	0.4	56
176	The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Molecular Psychiatry, 1999, 4, 317-327.	7.9	339
177	Brain iNOS: current understanding and clinical implications. Trends in Molecular Medicine, 1999, 5, 225-232.	2.6	112
178	Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life Sciences, 1999, 65, PL53-PL58.	4.3	47
179	The Impact of the Nonpeptide Corticotropin-Releasing Hormone Antagonist Antalarmin on Behavioral and Endocrine Responses to Stress. Endocrinology, 1999, 140, 79-86.	2.8	95
180	Circadian Interleukin-6 Secretion and Quantity and Depth of Sleep. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2603-2607.	3.6	94

MA-LI WONG

#	Article	IF	CITATIONS
181	Circumscribed lesion of the medial forebrain bundle area causes structural impairment of lymphoid organs and severe depression of immune function in rats. Molecular Psychiatry, 1998, 3, 397-404.	7.9	5
182	The nitric oxide hypothesis of aging. Experimental Gerontology, 1998, 33, 813-826.	2.8	138
183	Leptin. International Journal of Biochemistry and Cell Biology, 1998, 30, 1285-1290.	2.8	123
184	Sex Differences in Circulating Human Leptin Pulse Amplitude: Clinical Implications1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4140-4147.	3.6	154
185	Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 2541-2546.	7.1	258
186	Sex Differences in Circulating Human Leptin Pulse Amplitude: Clinical Implications. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4140-4147.	3.6	123
187	Interleukin (IL) 1β, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: Pathophysiological implications. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 227-232.	7.1	224
188	Endogenous Interleukin-1 Receptor Antagonist is Neuroprotective. Biochemical and Biophysical Research Communications, 1997, 234, 211-215.	2.1	136
189	Interleukin 1 receptor antagonist gene expression in rat pituitary in the systemic inflammatory response syndrome: pathophysiological implications. Molecular Psychiatry, 1997, 2, 99-103.	7.9	13
190	Human leptin levels are pulsatile and inversely related to pituitary–ardenal function. Nature Medicine, 1997, 3, 575-579.	30.7	637
191	Pathways and mechanisms for cytokine signaling of the central nervous system Journal of Clinical Investigation, 1997, 100, 2941-2947.	8.2	187
192	The hypothalamic-pituitary-adrenal axis in anorexia nervosa. Psychiatry Research, 1996, 62, 75-83.	3.3	138
193	Identification of Hypothalamic Transcripts Upregulated by Antidepressants. Biochemical and Biophysical Research Communications, 1996, 229, 275-279.	2.1	23
194	IL-1β, IL-1 receptor type I and iNOS gene expression in rat brain vasculature and perivascular areas. NeuroReport, 1996, 7, 2445-2448.	1.2	70
195	Inducible nitric oxide synthase gene expression in the brain during systemic inflammation. Nature Medicine, 1996, 2, 581-584.	30.7	272
196	Interleukin 1β and fever. Nature Medicine, 1996, 2, 1314-1315.	30.7	12
197	Cytokines in the Brain. Neuroscience Intelligence Unit, 1996, , 3-20.	0.5	7
198	Rat LCR1: cloning and cellular distribution of a putative chemokine receptor in brain. Molecular Psychiatry, 1996, 1, 133-40.	7.9	36

#	Article	IF	CITATIONS
199	Stress system abnormalities in melancholic and atypical depression: molecular, pathophysiological, and therapeutic implications. Molecular Psychiatry, 1996, 1, 257-64.	7.9	54
200	Localization of urocortin messenger RNA in rat brain and pituitary. Molecular Psychiatry, 1996, 1, 307-12.	7.9	58
201	Focal cerebral ischemia induces CRH mRNA in rat cerebral cortex and amygdala. NeuroReport, 1995, 6, 1785-1788.	1.2	50
202	Corticotropin Releasing Hormone in the Pathophysiology of Melancholic and Atypical Depression and in the Mechanism of Action of Antidepressant Drugs. Annals of the New York Academy of Sciences, 1995, 771, 716-729.	3.8	189
203	Localization of Interleukin-1βP Converting Enzyme mRNA in Rat Brain Vasculature: Evidence that the Genes Encoding the Interleukin-1 System Are Constitutively Expressed in Brain Blood Vessels. NeuroImmunoModulation, 1995, 2, 141-148.	1.8	47
204	The gene encoding for the novel transacting factor proopiomelanocortin corticotropin-releasing hormone responsive element binding protein 1 (PCRH-REB-1) is constitutively expressed in rat pituitary and in discrete brain regions containing CRH or CRH receptors: pathophysiological implications Endocrinology, 1995, 136, 4709-4712.	2.8	8
205	A molecular mechanism for stress-induced alterations in susceptibility to disease. Lancet, The, 1995, 346, 104-106.	13.7	36
206	The gene encoding for the novel transacting factor proopiomelanocortin corticotropin-releasing hormone responsive element binding protein 1 (PCRH-REB-1) is constitutively expressed in rat pituitary and in discrete brain regions containing CRH or CRH receptors: pathophysiological implications. Endocrinology, 1995, 136, 4709-4712.	2.8	1
207	Pulsatility of 24-Hour Concentrations of Circulating Interleukin-1-Alpha in Healthy Women: Analysis of Integrated Basal Levels, Discrete Pulse Properties, and Correlation with Simultaneous Interleukin-2 Concentrations. NeuroImmunoModulation, 1994, 1, 242-250.	1.8	6
208	Localization of corticotropin-releasing hormone (CRH) receptor mRNA in adult rat brain by in situ hybridization histochemistry Endocrinology, 1994, 135, 2275-2278.	2.8	82
209	Localization of Interleukin 1 Type I Receptor mRNA in Rat Brain. NeuroImmunoModulation, 1994, 1, 110-115.	1.8	115
210	Localization of Stem Cell Factor mRNA in Adult Rat Hippocampus. NeuroImmunoModulation, 1994, 1, 181-187.	1.8	20
211	Localization of corticotropin-releasing hormone (CRH) receptor mRNA in adult rat brain by in situ hybridization histochemistry. Endocrinology, 1994, 135, 2275-2278.	2.8	33
212	Activity-induced anorexia in rats does not affect hypothalamic neuropeptide gene expression chronically. International Journal of Eating Disorders, 1993, 13, 399-405.	4.0	19
213	Differential effects of kindled and electrically induced seizures on a glutamate receptor (GluR1) gene expression. Epilepsy Research, 1993, 14, 221-227.	1.6	59
214	Characterization and Functional Expression of a Somatostatin Receptor Coupled to Adenylyl Cyclase. Molecular and Cellular Neurosciences, 1993, 4, 259-266.	2.2	3
215	In Situ Hybridization Techniques for Localization of Interleukin 1 and Interleukin 1 Receptor Antagonist mRNA in Brain. Methods in Neurosciences, 1993, 16, 81-99.	0.5	3
216	Neutrophil-activating peptide-1 /interleukin-8 mRNA is localized in rat hypothalamus and hippocampus. NeuroReport, 1992, 3, 753-756.	1.2	25

#	Article	IF	CITATIONS
217	Induction of constitutive heat shock protein 73 mRNA in the dentate gyrus by seizures. Molecular Brain Research, 1992, 13, 19-25.	2.3	28
218	Polyamine effects uponN-methyl-D-aspartate receptor functioning: differential alteration by glutamate and glycine site antagonists. Brain Research, 1991, 561, 285-291.	2.2	11
219	Localization of Interleukin-1 Receptor Antagonist mRNA in Rat Brain. Endocrinology, 1991, 129, 562-564.	2.8	113
220	Functional Expression and RNA Binding Analysis of the Interferon-Induced, Double-Stranded RNA-Activated, 68,000- <i>M</i> _r Protein Kinase in a Cell-Free System. Molecular and Cellular Biology, 1991, 11, 5497-5505.	2.3	96
221	Prefrontal-Type Cognitive Deficits and Chronic Psychiatric Conditions. Archives of General Psychiatry, 1988, 45, 1054.	12.3	0
222	Pharmacogenomics of Major Depression and Antidepressant Treatment. , 0, , 379-395.		0